ReHealth AI, a pioneering company in preventive healthcare AI, has successfully closed a ¥4 million seed funding round, reaching a post-money valuation of ¥25 million. The undisclosed investor is providing both capital and strategic business support to advance the company's mission. ReHealth AI aims to resolve a fundamental challenge in preventive medicine by creating an infrastructure that makes preventive outcomes verifiable and billable.
Addressing a Critical Gap in Preventive Healthcare
China faces a significant public health challenge with over 330 million people suffering from cardiovascular diseases, a majority of which are preventable. Despite this, preventive care remains on the periphery of the established medical payment system. The primary obstacle is the lack of a standardized method for quantifying the effectiveness of interventions, which hinders commercial viability.
This infrastructural deficit creates a bottleneck for the entire preventive care industry, as providers cannot demonstrate return on investment. Consequently, insurance companies lack the auditable evidence needed to process settlements for preventive services. This systemic issue has historically prevented preventive medicine from being integrated into mainstream healthcare financing and policy.
A Novel Platform for Preventive Settlement
ReHealth AI is tackling this problem with its innovative, four-part AI platform designed specifically for "preventive settlement." The system first identifies high-risk individuals one to three years in advance using a predictive model with high accuracy. It then generates customized, clinical-grade intervention plans tailored to each patient's specific risk factors.
The platform's core innovation lies in its final two stages: attribution and settlement. It employs Propensity Score Matching (PSM), a causal inference method, to statistically measure the real-world impact of the interventions. These verified outcomes are then compiled into standardized reports, providing payers with the concrete evidence needed for settlement.
Technology and Market Strategy
To ensure data security and regulatory compliance, the platform is built on a medical-grade federated learning framework. This technology allows the AI model to be trained without sensitive patient data ever leaving the hospital's secure environment. The company has also proactively protected its core methodologies by filing for four patents and five software copyrights.
The company's initial go-to-market strategy focuses on cardiovascular disease, offering its B2B services to medical institutions, insurance companies, and corporate wellness providers. ReHealth AI is already making significant commercial progress, with three medical institutions currently in substantive negotiations. This targeted approach aims to establish a proven business model before scaling.
According to CEO Chen Peijun, the seed funding is dedicated to validating the technology's clinical acceptance and proving its effectiveness with data. The ultimate goal is to secure at least one paying partner, which he believes will naturally lead to commercialization. Following this, the company plans to apply its infrastructure to other high-cost conditions like diabetes and cancer screening.
This seed funding marks a crucial step for ReHealth AI as it works to build the essential infrastructure for a new era of preventive medicine. The capital will enable the company to conduct clinical tests, secure regulatory approvals, and fully engineer its unique prediction-to-settlement loop. With supportive government policies and a growing industry shift toward health management, ReHealth AI is well-positioned to bridge the gap between preventive action and financial reimbursement.